Description: Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Home Page: www.silence-therapeutics.com
72 Hammersmith Road
London,
W14 8TH
United Kingdom
Phone:
44 20 3457 6900
Officers
| Name | Title |
|---|---|
| Mr. Craig A. Tooman M.B.A. | President, CEO & Executive Director |
| Ms. Rhonda L. Hellums | Executive VP, CFO & Secretary |
| Dr. Steven J. Romano M.D. | Executive VP and Chief Research & Development Officer |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer |
| Ms. Gem Gokmen Hopkins | Head of IR & Corporate Communications |
| Ms. Gianine Esposito | Chief Human Resources Officer |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Senior VP and Chief Intellectual Property & Innovation Officer |
| Dr. Eric Floyd M.B.A., M.S., Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Mr. J.P. Gabriel | Chief Technical Operations Officer |
| Mr. Curtis Rambaran M.D. | Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3648 |
| Price-to-Sales TTM: | 12.8726 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 109 |